Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of Health
Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of Health
批准号:
10751275
负责人:
Jiang Bian
金额:
$256.15万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2026-08-31
关键词:
2019-nCoVAcuteAdoptionAdvanced DevelopmentAir PollutionAlabamaAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAntigensCOVID-19COVID-19 diagnosisCOVID-19 impactClinicalClinical DataCognition DisordersCognitiveComplexConnecticutDataData SourcesDementiaDisease ProgressionElectronic Health RecordEnvironmentEpidemiologyExposure toFloridaFutureGeneral PopulationHealthHeterogeneityImpaired cognitionIncidenceIndividualKnowledgeLaboratoriesLinkMassachusettsMeasuresMedical HistoryMedicineMemory DisordersMethodsModelingNatureNeighborhoodsNeurologicNeurological outcomeNew HampshireNew JerseyNew YorkPathway interactionsPatientsPatternPhenotypePlayPolymerase Chain ReactionPositioning AttributePost-Acute Sequelae of SARS-CoV-2 InfectionPragmatic clinical trialPredispositionPrevention strategyPublishingResearchRiskRisk FactorsRoleSARS-CoV-2 positiveSelection BiasSeveritiesSocial EnvironmentSyndromeTestingVital StatisticsWorkbody systemcausal modelcohortcoronavirus diseasedata registrydeep learningdeprivationelectronic health record systemhealth determinantsmild cognitive impairmentmortalityneurologic sequelae of COVID-19novelpandemic diseaserepositoryroutine caresocialsocial influencesuccesstreatment strategywalkability
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The global pandemic of the 2019 novel coronavirus disease (COVID-19) has severe consequences. Recent
studies showed that individuals with COVID-19 had increased risk of an array of postacute incident neurologic
sequelae, including cognition and memory disorders, in 12 months after COVID-19 diagnosis. Despite
elevated risks of postacute neurologic outcomes of COVID-19 observed in the general population, little is
known about Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in cognitively impaired individuals (e.g.,
those with mild cognitive impairment [MCI] and Alzheimer’s disease [AD]/AD-related dementias [ADRD]) and
how it may impact their subsequent disease progression. The rapid adoption of electronic health record (EHR)
systems has made longitudinal clinical data available for research, especially for individuals with MCI or
AD/ADRD who engage in frequent routine care. However, existing large EHR-based COVID-19 cohorts do not
specifically focus on cognitively impaired individuals have several key limitations, including (1) missing or
inaccurate information on cognitive impairment, (2) challenges to characterize disease progression in
individuals with MCI or AD/ADRD, and (3) robust causal modeling approaches that can account for the
complex confounding and selection biases in observational RWD. More importantly, little is known about
factors contributing to PASC and subsequent disease progression in cognitively impaired individuals with
COVID-19. It has long been recognized that social and environmental determinants of health (SEDH) play
important roles in cognitive health. Exposures to multiple SEDH have been associated with MCI and
AD/ADRD. Our recent studies (R21ES032762 and the RECOVER Initiative) also found that SEDH are
associated with COVID-19 incidence, severity, mortality, and PASC in the general population. Individuals are
exposed to multiple SEDH simultaneously, and the exposome is an ideal framework to rigorously examine how
SEDH impacts cognitively impaired individuals’ susceptibility to PASC and subsequent disease progression.
Building upon our prior and ongoing work on COVID-19 and PASC in the general population with the
RECOVER Initiative, sub-phenotyping and disease progression modeling, and multiple SEDH, we will (1)
understand the epidemiology of PASC in individuals with MCI or AD/ADRD with high-throughput causal
inference approaches, (2) examine the impacts of COVID-19 and PASC on subsequent disease progression in
individuals with MCI or AD/ADRD with a novel dynamic topic modeling approach, and (3) assess how SEDH
contribute to PASC and subsequent disease progression in individuals with MCI or AD/ADRD with the
exposome conceptual framework. This project will fill important knowledge gaps on our understanding of,
especially SEDH’s contributions to, risks of PASC and subsequent disease progression in individuals with
cognitive impairment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System
-
批准号:10753675
-
项目类别:
-
资助金额:$115.53万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
Disparities of Alzheimer's disease progression in sexual and gender minorities
-
批准号:10590413
-
项目类别:
-
资助金额:$80.96万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
Artificial Intelligence and Counterfactually Actionable Responses to End HIV (AI-CARE-HIV)
-
批准号:10699171
-
项目类别:
-
资助金额:$73.14万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
An end-to-end informatics framework to study Multiple Chronic Conditions (MCC)'s impact on Alzheimer's disease using harmonized electronic health records
-
批准号:10728800
-
项目类别:
-
资助金额:$116.82万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
AI-ADRD: Accelerating interventions of AD/ADRD via Machine learning methods
-
批准号:10682237
-
项目类别:
-
资助金额:$234.89万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations (PLuS2)
-
批准号:10752848
-
项目类别:
-
资助金额:$55.65万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI
-
批准号:10608470
-
项目类别:
-
资助金额:$82.02万
-
财政年份:2023
-
负责人:Jiang Bian
-
依托单位:
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge
-
批准号:10576853
-
项目类别:
-
资助金额:$77.52万
-
财政年份:2022
-
负责人:Jiang Bian
-
依托单位:
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge
-
批准号:10392169
-
项目类别:
-
资助金额:$80.75万
-
财政年份:2022
-
负责人:Jiang Bian
-
依托单位:
PANDA-MSD: Predictive Analytics via Networked Distributed Algorithms for Multi-System Diseases
-
批准号:10368562
-
项目类别:
-
资助金额:$121.22万
-
财政年份:2022
-
负责人:Jiang Bian
-
依托单位:
PANDA-MSD: Predictive Analytics via Networked Distributed Algorithms for Multi-System Diseases
-
批准号:10677539
-
项目类别:
-
资助金额:$119.57万
-
财政年份:2022
-
负责人:Jiang Bian
-
依托单位:
The External Exposome and COVID-19 Severity
-
批准号:10531662
-
项目类别:
-
资助金额:$23.27万
-
财政年份:2021
-
负责人:Jiang Bian
-
依托单位:
Advancing Drug Repositioning for Alzheimer’s Disease using Real-world Data
-
批准号:10374177
-
项目类别:
-
资助金额:$76.13万
-
财政年份:2021
-
负责人:Jiang Bian
-
依托单位:
Optimizing the Population Representativeness of Older Adults in Cancer Trials
-
批准号:10180066
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2021
-
负责人:Jiang Bian
-
依托单位:
Advancing Drug Repositioning for Alzheimer’s Disease using Real-world Data
-
批准号:10330045
-
项目类别:
-
资助金额:$79.87万
-
财政年份:2021
-
负责人:Jiang Bian
-
依托单位:
The External Exposome and COVID-19 Severity
-
批准号:10174270
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2020
-
负责人:Jiang Bian
-
依托单位:
Examine the risk of Alzheimer's disease in sexual and gender minorities
-
批准号:10283696
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2020
-
负责人:Jiang Bian
-
依托单位:
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
-
批准号:10636657
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2020
-
负责人:Jiang Bian
-
依托单位:
The benefits and harms of lung cancer screening in Florida
-
批准号:10576300
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2020
-
负责人:Jiang Bian
-
依托单位:
Optimizing Alzheimer's Disease Clinical Trial Generalizability
-
批准号:10091637
-
项目类别:
-
资助金额:$37.08万
-
财政年份:2020
-
负责人:Jiang Bian
-
依托单位:
海外基金